![]() |
市场调查报告书
商品编码
1395011
人工胰臟设备系统 (APDS) 市场 - 按设备类型(阈值暂停设备系统、控制范围 (CTR) 系统、控制目标 (CTT) 系统)、按最终用途(医院和诊所、家庭护理) - 全球预测,2023- 2032Artificial Pancreas Device Systems (APDS) Market - By Device Type (Threshold Suspend Device Systems, Control-to-range (CTR) Systems, Control-to-target (CTT) Systems), By End-use (Hospitals and Clinics, Homecare) - Global Forecast, 2023-2032 |
在广泛的研究和开发工作取得可喜成果的推动下,全球人工胰臟设备系统 (APDS) 市场 2023 年至 2032 年间的CAGR将达到 8.8%。突破性成果展示了这些系统在管理糖尿病方面的功效,为加强病患照护带来了希望。
例如,2023 年3 月,儿科人工胰臟(PEDAP) 试验是一项在美国三个儿科糖尿病中心进行的为期13 週的随机对照研究,结果显示,透过人工胰臟可以增强2 至5 岁患有1 型糖尿病的幼儿的血糖控制。胰臟技术。在美国国立卫生研究院下属的国家糖尿病、消化和肾臟疾病研究所 (NIDDK) 的资助下,研究结果发表在《新英格兰医学杂誌》。该技术也称为闭环控制,可作为整合式糖尿病管理系统,利用连续血糖监测 (CGM) 来追踪血糖水平,并根据需要透过胰岛素帮浦自动管理胰岛素。
随着临床试验显示出正面的结果,对 APDS 的需求不断增长。该技术在自动化胰岛素输送和维持血糖水平方面的潜力引起了人们的关注,将 APDS 定位为糖尿病管理创新的灯塔。这种乐观情绪推动了人工胰臟装置系统 (APDS) 市场的扩张,因为它正朝着改变全球糖尿病照护的方向发展。
整个人工胰臟设备系统(APDS)市场根据设备类型、最终用途和区域进行分类。
从 2023 年到 2032 年,控制范围 (CTR) 设备细分市场将呈现显着增长。这些创新系统可在目标范围内提供精确的血糖管理,重新定义糖尿病护理。 CTR 技术可确保最佳血糖水平,降低低血糖和高血糖风险。 CTR 设备能够根据连续血糖监测仪 (CGM) 的即时资料微调胰岛素输送,彻底改变了糖尿病管理。社交胰臟设备系统市场收入的成长得益于改善糖尿病患者健康结果和提高生活品质的承诺,从而增强了这些先进系统的吸引力。
家庭护理领域从 2023 年到 2032 年将实现显着的CAGR。APDS 提供了变革性的转变,使个人能够在家中方便地管理自己的状况。借助利用连续血糖监测仪和自动胰岛素输送的整合系统,APDS 使患者无需住院即可维持最佳血糖水平。这一趋势反映了向个人化、便利照护的根本转变,随着居家照护成为现代糖尿病管理策略的基石,推动了人工胰臟设备系统市场的发展。
欧洲人工胰臟装置系统 (APDS) 市场从 2023 年到 2032 年将呈现出值得称讚的CAGR。该地区采用 APDS 技术,寻求高效、自动化的血糖控制解决方案。 APDS 专注于提高患者治疗效果和生活质量,整合了连续血糖监测和胰岛素输送,因其便利性和有效性而受到关注。欧洲市场的成长反映了对创新、以患者为中心的糖尿病护理的渐进方法,促进了整个非洲大陆对 APDS 解决方案不断增长的需求。例如,2023 年 11 月,英格兰和威尔斯的 NHS 计划为超过 150,000 名 1 型糖尿病患者(包括成人和儿童)提供人工胰腺,专家称讚此举是革命性的,可以挽救生命。
Global Artificial Pancreas Device Systems (APDS) Market will witness 8.8% CAGR between 2023 and 2032, propelled by promising outcomes from extensive research and development efforts. Breakthroughs showcase the efficacy of these systems in managing diabetes, offering hope for enhanced patient care.
For instance, in March 2023, The Pediatric Artificial Pancreas (PEDAP) Trial, a 13-week randomized controlled study across three pediatric diabetes centers in the United States, revealed enhanced blood glucose control in toddlers aged 2 to 5 with type 1 diabetes through Artificial Pancreas Technology. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, findings were published in the New England Journal of Medicine. This technology, also termed closed-loop control, acts as an integrated diabetes management system, utilizing continuous glucose monitoring (CGM) to track glucose levels and automatically administering insulin as necessary via an insulin pump.
As clinical trials demonstrate positive results, the demand for APDS grows. The technology's potential to automate insulin delivery and maintain glucose levels garners attention, positioning APDS as a beacon of innovation in diabetes management. This optimism fuels the artificial pancreas device systems (APDS) market expansion as it moves towards transforming diabetes care globally.
The overall Artificial Pancreas Device Systems (APDS) Market is classified based on device type, end-use, and region.
Control-to-range (CTR) devices segment will exhibit significant growth from 2023 to 2032. Offering precise glucose management within target ranges, these innovative systems redefine diabetes care. CTR technology ensures optimal blood glucose levels, mitigating both hypoglycemia and hyperglycemia risks. With their ability to fine-tune insulin delivery based on real-time data from continuous glucose monitors (CGM), CTR devices revolutionize diabetes management. The art of social pancreas device systems market revenue is propelled by the promise of improved health outcomes and enhanced quality of life for individuals navigating diabetes, amplifying the appeal of these advanced systems.
Homecare segment will register a noteworthy CAGR from 2023 to 2032. APDS offers a transformative shift, allowing individuals to manage their condition conveniently at home. With integrated systems utilizing continuous glucose monitors and automated insulin delivery, APDS empowers patients to maintain optimal blood glucose levels without hospital visits. This trend reflects a fundamental shift towards personalized, accessible care, driving the artificial pancreas device system market as home care becomes a cornerstone in modern diabetes management strategies.
Europe artificial pancreas device systems (APDS) market will showcase a commendable CAGR from 2023 to 2032. The region embraces APDS technology, seeking efficient, automated solutions for glucose control. With a focus on enhancing patient outcomes and quality of life, APDS integrates continuous glucose monitoring and insulin delivery, gaining traction for its convenience and efficacy. The market's growth in Europe reflects a progressive approach towards innovative, patient-centric diabetes care, fostering a rising demand for APDS solutions across the continent. For instance, in November 2023, The NHS in England and Wales planned to provide over 150,000 individuals, both adults and children with type 1 diabetes, with an artificial pancreas-a move praised by experts as revolutionary and life-saving.